Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130Cas

Current interest in proteasome inhibitors for cancer therapy has stimulated considerable research efforts to identify the molecular pathway to their cytotoxicity with a view to identifying the mechanisms of sensitivity and resistance as well as informing the development of new drugs. Zhao and Vuori...

Descripción completa

Detalles Bibliográficos
Autores principales: Chauhan, Dharminder, Anderson, Kenneth C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3203852/
https://www.ncbi.nlm.nih.gov/pubmed/22034840
http://dx.doi.org/10.1186/1741-7007-9-72
_version_ 1782215139673505792
author Chauhan, Dharminder
Anderson, Kenneth C
author_facet Chauhan, Dharminder
Anderson, Kenneth C
author_sort Chauhan, Dharminder
collection PubMed
description Current interest in proteasome inhibitors for cancer therapy has stimulated considerable research efforts to identify the molecular pathway to their cytotoxicity with a view to identifying the mechanisms of sensitivity and resistance as well as informing the development of new drugs. Zhao and Vuori describe this month in BMC Biology experiments indicating a novel role of the adaptor protein p130Cas in sensitivity to apoptosis induced not only by proteasome inhibitors but also by the unrelated drug doxorubicin. See research article: http:// http://www.biomedcentral.com/1741-7007/9/73
format Online
Article
Text
id pubmed-3203852
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32038522011-10-29 Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130Cas Chauhan, Dharminder Anderson, Kenneth C BMC Biol Commentary Current interest in proteasome inhibitors for cancer therapy has stimulated considerable research efforts to identify the molecular pathway to their cytotoxicity with a view to identifying the mechanisms of sensitivity and resistance as well as informing the development of new drugs. Zhao and Vuori describe this month in BMC Biology experiments indicating a novel role of the adaptor protein p130Cas in sensitivity to apoptosis induced not only by proteasome inhibitors but also by the unrelated drug doxorubicin. See research article: http:// http://www.biomedcentral.com/1741-7007/9/73 BioMed Central 2011-10-28 /pmc/articles/PMC3203852/ /pubmed/22034840 http://dx.doi.org/10.1186/1741-7007-9-72 Text en Copyright ©2011 Chauhan and Anderson; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Chauhan, Dharminder
Anderson, Kenneth C
Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130Cas
title Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130Cas
title_full Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130Cas
title_fullStr Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130Cas
title_full_unstemmed Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130Cas
title_short Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130Cas
title_sort proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130cas
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3203852/
https://www.ncbi.nlm.nih.gov/pubmed/22034840
http://dx.doi.org/10.1186/1741-7007-9-72
work_keys_str_mv AT chauhandharminder proteasomeinhibitionthepursuitofnewcancertherapeuticsandtheadaptormoleculep130cas
AT andersonkennethc proteasomeinhibitionthepursuitofnewcancertherapeuticsandtheadaptormoleculep130cas

Ejemplares similares